Celgene, Acceleron submit FDA application for billed blockbuster luspatercept — will they get priority review?
Celgene and their partners at Acceleron are counting on their red blood cell boosting drug to win a speedy review as they submitted a marketing application for the biologic on Friday. For the big biotech — tarnished by a poor performance under CEO Mark Alles — the drug is one of the top five in its pipeline, critical for the mighty $74 billion Bristol-Myers Squibb takeover.
The drug, luspatercept, has been developed to manage anemia resulting from myelodysplastic syndrome (MDS) as well as beta thalassemia and has inspired peak sales estimates of $2 billion plus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.